Clinical Utility and Outcome Prediction of Cardiovascular Computed Tomography (PREDICT-CT)
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Mar 29, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PREDICT-CT trial is studying how well cardiovascular computed tomography (CCTA) can help doctors predict health outcomes for patients with heart-related issues, specifically those with coronary artery disease. The researchers will look at both past and current information from participants who are having this imaging test, connecting it with lab results and other health data to see how effectively CCTA can guide treatment decisions.
To be part of this study, you need to be an adult over 18 years old who is scheduled to have a CCTA for medical reasons. There are no specific health conditions that would exclude you from participating. If you join the study, you’ll simply provide consent and allow the researchers to use your health information for their analysis. This trial is currently recruiting participants, and they welcome individuals of all genders within the eligible age range. Your involvement could help improve how doctors assess and treat heart conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult individual \>18 years
- • Undergoing clinically indicated CCTA
- • Signed informed consent or waiver
- Exclusion Criteria:
- • None
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Christoph Gräni, MD, PhD
Principal Investigator
Department of Cardiology, University Hospital Bern,
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials